Breast Cancer | Clinical

Innovations in the Treatment of HER2+ Breast Cancer

May 11, 2021

In an interview with Targeted Oncology, Komal Jhaveri, MD, FACP, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses HER2-positive metastatic breast cancer innovations, treatments, and upcoming studies.

ODAC Votes to Continue Approval of Atezolizumab/Nab-Paclitaxel for Advanced or Metastatic TNBC

April 27, 2021

The FDA's Oncologic Drugs Advisory Committee voted 7 to 2 in favor of the continued approval of atezolizumab in combination with nab-paclitaxel for the treatment of patients with advanced or metastatic triple-negative breast cancer whose tumors are positive for PD-L1 expression.

Breast Cancer Testing May Benefit from the Multi-Omics Approach Over Biomarker Assessment Alone

April 13, 2021

For patients with metastatic breast cancer, research suggests that utilizing a multi-omics approach to personalized therapy that incorporates information about actionable oncogenic drivers with critical biological data may be feasible and better than DNA sequencing alone.